Volume 10 Supplement 1

Co-stimulation blockade: from bench to bedside

Reviews

Edited by Jörg J Goronzy

Publication of this supplement has been sponsored by Bristol-Myers Squibb Company

  1. Review

    T cells in rheumatoid arthritis

    Over the past decade and a half, advances in our understanding of the pathogenesis of immune-mediated diseases such as rheumatoid arthritis (RA) have translated directly into benefit for patients. Much of this...

    Andrew P Cope

    Arthritis Research & Therapy 2008 10(Suppl 1):S1

    Published on: 15 October 2008

  2. Review

    T-cell co-stimulatory pathways in autoimmunity

    T-cell activation and differentiation depend on the signal strength received by the T-cell receptor and on signals provided by co-stimulatory molecules. The most prominent co-stimulatory molecule is CD28, whic...

    Jörg J Goronzy and Cornelia M Weyand

    Arthritis Research & Therapy 2008 10(Suppl 1):S3

    Published on: 15 October 2008

  3. Review

    Translating co-stimulation blockade into clinical practice

    Currently available information from clinical trials and open-label extensions suggest that abatacept is a good alternative to other biologicals in rheumatoid arthritis. Although at first glance the efficacy o...

    Rene Westhovens and Patrick Verschueren

    Arthritis Research & Therapy 2008 10(Suppl 1):S4

    Published on: 15 October 2008

  4. Review

    Abatacept in the treatment of rheumatoid arthritis

    T-cell biology has regained importance in the pathogenesis of rheumatoid arthritis. Despite the significant improvements associated with the introduction of tumor necrosis factor-α blockade, reasonable proport...

    Maya H Buch, Edward M Vital and Paul Emery

    Arthritis Research & Therapy 2008 10(Suppl 1):S5

    Published on: 15 October 2008

Logo

Advertisement